Business
Faron announces R&D Day in February 2018
Faron announces R&D Day in February 2018.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 3032Z Faron Pharmaceuticals Oy 14 December 2017 \n\nFaron Pharmaceuticals Ltd\n(\"Faron\" or the \"Company\")\n \nFaron announces R&D Day in February 2018\n \n \nTURKU - FINLAND, 14 December 2017 - Faron Pharmaceuticals Ltd (\"Faron\") (LON: FARN), the clinical stage biopharmaceutical company, announces plans to host an R&D Day on Wednesday, 21 February 2018, at Panmure Gordon's offices, One New Change, London, EC4M 9AF. The event will provide an opportunity to hear about the Company, its R&D strategy and pipeline developments, with a focus on Clevegen, Faron's second wholly-owned pipeline product approaching the start of Phase I/II development in 2018.\n \nClevegen is a novel anti-Clever-1 antibody, which causes changes in the immune environment of solid tumours by switching immune suppressive M2 macrophages to immune active M1 macrophages. Based on this unique mechanism of action, promising pre-clinical data and human ex vivo data, Clevegen could have potential in a broad range of indications, including immuno-oncology, chronic infections and vaccination enhancement.\n \nThe R&D event will provide an update on Clevegen's manufacturing, regulatory and scientific progress, in addition to an update on the clinical development plan. The Phase I/II trial will target patients with liver, melanoma, ovarian and pancreatic cancer as part of an adaptive protocol design, which is currently under review by regulators, with feedback anticipated in early 2018.\n \nFaron will also provide an update on Traumakine, its lead wholly-owned product for the treatment of moderate to severe Acute Respiratory Distress Syndrome (ARDS) following the completion of recruitment in the Phase III INTEREST trial, and for which the top-line data are expected to become available in H1 2018.\n \nFor further information on the R&D day, or to register for the event, please contact Consilium Strategic Communications at [email protected] or telephone +44 (0)20 3709 5700.\n \n \nFor more information please contact:\n \nFaron Pharmaceuticals Ltd\nDr Markku Jalkanen, Chief Executive Officer\[email protected] \n \nConsilium Strategic Communications\nMary-Jane Elliott, Chris Welsh, Philippa Gardner, Lindsey Neville\nPhone: +44 (0)20 3709 5700\n...